52 studies found for:    "Acinic Cell Carcinoma"
Show Display Options
Rank Status Study
1 Recruiting Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: dasatinib;   Drug: erlotinib hydrochloride
2 Completed Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: triapine
3 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: dinaciclib;   Drug: Akt inhibitor MK2206;   Other: pharmacological study;   Other: laboratory biomarker analysis
4 Recruiting Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: alisertib;   Drug: gemcitabine
5 Active, not recruiting GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib;   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride;   Other: diagnostic laboratory biomarker analysis
6 Completed Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sorafenib tosylate;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
7 Not yet recruiting Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: selinexor;   Other: pharmacological study;   Other: laboratory biomarker analysis
8 Withdrawn Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Liver Metastases;   Lung Metastases;   Recurrent Breast Cancer;   Recurrent Pancreatic Cancer;   Stage IV Breast Cancer;   Stage IV Pancreatic Cancer
Interventions: Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: pharmacological study;   Biological: tumor-homing peptide iRGD
9 Recruiting ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Gallbladder;   Duct Cell Adenocarcinoma of the Pancreas;   Localized Unresectable Adult Primary Liver Cancer;   Periampullary Adenocarcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Gallbladder Cancer;   Recurrent Pancreatic Cancer;   Stage II Gallbladder Cancer;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer
Interventions: Drug: ADH-1;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
10 Not yet recruiting Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage I-III Pancreatic Cancer
Interventions: Drug: metformin hydrochloride;   Radiation: stereotactic radiosurgery
11 Completed Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: paclitaxel;   Drug: bryostatin 1;   Other: pharmacological study
12 Recruiting Combination Chemotherapy, Gemcitabine Hydrochloride, and Radiation Therapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: irinotecan hydrochloride;   Drug: fluorouracil;   Radiation: intensity-modulated radiation therapy;   Drug: gemcitabine hydrochloride
13 Active, not recruiting Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib;   Drug: sirolimus;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18
14 Recruiting Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: 5-fluorouracil;   Drug: capecitabine;   Radiation: radiation;   Procedure: surgery;   Drug: gemcitabine  hydrochloride
15 Recruiting CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
16 Suspended Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: gemcitabine hydrochloride;   Drug: WEE1 inhibitor MK-1775;   Other: placebo;   Other: pharmacological study;   Other: laboratory biomarker analysis
17 Recruiting Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: metformin hydrochloride;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis
18 Active, not recruiting Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: falimarev;   Biological: inalimarev;   Biological: sargramostim;   Other: laboratory biomarker analysis
19 Active, not recruiting Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: wild-type reovirus;   Drug: carboplatin;   Drug: paclitaxel;   Other: laboratory biomarker analysis
20 Recruiting Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma of Unknown Primary;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Diffuse Adenocarcinoma of the Stomach;   Duct Cell Adenocarcinoma of the Pancreas;   Intestinal Adenocarcinoma of the Stomach;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Carcinoma of Unknown Primary;   Metastatic Extrahepatic Bile Duct Cancer;   Mixed Adenocarcinoma of the Stomach;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Newly Diagnosed Carcinoma of Unknown Primary;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Rectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colon Cancer;   Stage IVA Gallbladder Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Gallbladder Cancer;   Stage IVB Rectal Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years